Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Accounts Payables (2020 - 2025)

SAB Biotherapeutics (SABS) has disclosed Accounts Payables for 6 consecutive years, with $6.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accounts Payables rose 288.5% year-over-year to $6.6 million, compared with a TTM value of $6.6 million through Dec 2025, up 288.5%, and an annual FY2025 reading of $6.6 million, up 288.5% over the prior year.
  • Accounts Payables was $6.6 million for Q4 2025 at SAB Biotherapeutics, down from $6.9 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $10.2 million in Q3 2022 and bottomed at $945927.0 in Q4 2023.
  • Average Accounts Payables over 5 years is $4.8 million, with a median of $5.0 million recorded in 2022.
  • The sharpest move saw Accounts Payables tumbled 90.46% in 2023, then skyrocketed 535.15% in 2024.
  • Year by year, Accounts Payables stood at $4.5 million in 2021, then skyrocketed by 122.45% to $9.9 million in 2022, then crashed by 90.46% to $945927.0 in 2023, then soared by 79.16% to $1.7 million in 2024, then skyrocketed by 288.5% to $6.6 million in 2025.
  • Business Quant data shows Accounts Payables for SABS at $6.6 million in Q4 2025, $6.9 million in Q3 2025, and $2.6 million in Q2 2025.